[144] Ionis Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Ionis Pharmaceuticals Form 144 notice: A proposed sale of 51,800 shares of common stock is reported to be executed through Stifel Nicolaus & Company, Inc. on 09/03/2025 with an aggregate market value of $3,152,698.00. The filing lists total shares outstanding of 159,391,229. Acquisition details for the shares to be sold are disclosed: 46,800 were acquired by option exercise on 01/03/2022, 7,537 were restricted stock units dated 01/15/2017, and 6,373 were restricted stock units dated 01/15/2016. The filing also reports sales by Frank Bennett in the past three months: 10,000 shares on 08/18/2025 for $439,776.00, and two sales on 09/02/2025 of 2,374 (proceeds $116,658.00) and 2,626 (proceeds $129,042.00). The filer signs a standard representation that no material nonpublic information is known. Other issuer contact and relationship fields are not populated in the provided content.

Positive

• Proposed sale disclosed with specific trade date (09/03/2025), broker (Stifel) and aggregate market value ($3,152,698.00).
• Acquisition history provided for the shares to be sold with dates and transaction types (option exercise and RSUs).
• Prior sales listed for the past three months with amounts and gross proceeds (totaling 15,000 shares).

Negative

• Issuer and relationship fields are not populated in the provided content, limiting context about the seller's role.
• Filing does not state whether the seller is an officer, director, or large shareholder in the provided excerpt.

Insights

Securities Analyst

TL;DR: Routine insider sale filing disclosing 51,800 shares for $3.15M, with prior small sales by Frank Bennett.

The Form 144 is procedural: it notifies the SEC of a proposed sale of 51,800 Ionis common shares through Stifel on 09/03/2025 valued at $3,152,698. The filing details the acquisition method and dates for the lots to be sold, indicating option exercise and restricted stock unit origins. Reported prior sales by Frank Bennett total 15,000 shares across August and September 2025 with disclosed gross proceeds. The filing does not include issuer relationship or additional context about the seller's role, limiting inference about insider status or intent.

Corporate Governance Expert

TL;DR: Disclosure appears compliant but lacks populated issuer relationship and contact fields, leaving some contextual gaps.

The submitted Form 144 contains the essential trading specifics required for Rule 144 notices: class, broker, amounts, acquisition dates, and past three-month sales. However, several issuer information fields (issuer contact, relationship to issuer) are blank in the provided content, which reduces transparency about the seller's capacity. The filing includes the statutory attestation regarding absence of material nonpublic information, consistent with rule requirements.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	51800	3152698.00	159391229	09/03/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/03/2022	Option Exercise	Issuer			46800	09/03/2025	Cash
Common Stock	01/15/2017	Restricted Stock Units	Issuer			7537	01/15/2017	Cash
Common Stock	01/15/2016	Restricted Stock Units	Issuer			6373	01/15/2016	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Frank Bennett 2855 Gazette Ct Carlsbad CA 92010	Common Stock	08/18/2025	10000	439776.00
Frank Bennett 2855 Gazette Ct Carlsbad CA 92010	Common Stock	09/02/2025	2374	116658.00
Frank Bennett 2855 Gazette Ct Carlsbad CA 92010	Common Stock	09/02/2025	2626	129042.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Ionis (IONS) Form 144 report?

The filing reports a proposed sale of 51,800 Ionis common shares through Stifel on 09/03/2025 with aggregate market value $3,152,698.00.

How were the shares being sold acquired?

The shares listed were acquired via option exercise on 01/03/2022 (46,800 shares) and as restricted stock units on 01/15/2017 (7,537) and 01/15/2016 (6,373).

Did the filer sell any Ionis shares in the prior three months?

Yes. The filing discloses Frank Bennett sold 10,000 shares on 08/18/2025 for $439,776.00, and on 09/02/2025 sold 2,374 (proceeds $116,658.00) and 2,626 (proceeds $129,042.00).

Who is the broker handling the proposed sale?

The broker named in the Form 144 is Stifel Nicolaus & Company, Inc.

Are there any undisclosed issuer details in the filing?

Yes. The provided content does not populate issuer contact, SEC file number, or the seller's relationship to the issuer.